|
![]() |
|
|
Nortriptyline
drug data and news
Nortriptyline drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Nortriptyline | ||
| Brand Names/Synonyms | AVENTYL HCL; Acetexa; Allegron; Altilev; Amitryptyline, Demethyl-; Ateben; Avantyl; Aventyl; Aventyl Hcl; Demethylamitriptylene; Demethylamitriptyline; Demethylamitryptyline; Desitriptilina; Desmethylamitriptyline; Lumbeck; Noramitriptyline; Noritren; Nortrilen; Nortriptyline; Nortriptyline Hcl; Nortryptiline; Norzepine; PAMELOR; Pamelor; Psychostyl; Sensaval; Sensival Ventyl; Sesaval; Vividyl | ||
| Indication | Depression | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Similar to protriptyline, nortriptyline is a tricyclic antidepressant of the dibenzocycloheptene type and is the active metabolite of amitriptyline. | ||
| Mechanism Of Action | It is believed that nortriptyline either inhibits the reuptake of the neurotransmitter serotonin at the neuronal membrane or acts at beta-adrenergic receptors. Tricyclic antidepressants do not inhibit monoamine oxidase nor do they affect dopamine reuptake. | ||
| Nortriptyline News (When available) |
Brain white-matter hyperintensities and treatment outcome in major ... Feb 8, 2006 STAR*D Preliminary Findings Provide Clearer Picture of Major ... Feb 27, 2006 Hepatitis C Treatment for People With Severe Mental Illness Feb 28, 2006 Antidepressants: Are they safe during pregnancy? Feb 22, 2006 Health Tip: Drugs to Avoid While Breast-Feeding Feb 16, 2006 Consumer Reports Medical Guide Addresses Differing Side Effects of ... Feb 10, 2006 Six Months of Treatment for Depression: Outcome and Predictors of ... Jan 24, 2006 Comorbid Tobacco Dependence and Psychiatric Disorders Jan 23, 2006 Ask the Clinician: Answers to Readers' Questions Jan 9, 2006 Jaw malady continues to be poorly understood Jan 29, 2006 Brief Reports: Patterns of Psychotropic Medication Use by Race ... Jan 25, 2006 Income may influence antidepressant response Jan 13, 2006 Six Months of Treatment for Depression: Outcome and Predictors of ... Jan 24, 2006 An open and shut case Dec 10, 2005 ABC News' Dr. Tim Answers Questions About Smoking Nov 11, 2005 Evaluation of Reboxetine, a Noradrenergic Antidepressant, for the ... Sep 23, 2005 Prevalence and Treatment of Depression in Parkinson’s Disease Sep 24, 2005 Impact of Cluster C Personality Disorders on Outcomes of Acute and ... Sep 24, 2005 Breaking the Teeth -- Grinding Habit Sep 22, 2005 Many meds don't mix with the sun Sep 21, 2005 Evaluation of Reboxetine, a Noradrenergic Antidepressant, for the ... Sep 6, 2005 Prognosis of Depression in Old Age Compared to Middle Age: A ... Aug 31, 2005 Seizures After a Bier Block with Clonidine and Lidocaine: Is ... Aug 22, 2005 Best Treatments for Lasting Shingles Pain Jul 25, 2005 What to Do With a Patient Who Smokes Jul 26, 2005 Palliative Pain Management: When Both Pain and Suffering Hurt Jul 15, 2005 Acute Akathisia Associated With Quetiapine Use Jul 6, 2005 Heat has its own set of medical problems Jul 26, 2005 Antidepressants: 1st Choice for Nerve Pain Jul 19, 2005 Easing The Pain Jul 18, 2005 Acute Akathisia Associated With Quetiapine Use Jul 6, 2005 Pharmac denies attack over critical articles Jun 28, 2005 Improving the Rates of Quitting Smoking for Veterans With ... Jun 30, 2005 Advances in Pharmacogenomics Reduce Side Effects and Save Lives Jul 5, 2005 A continuing headache Jul 2, 2005 Symptoms of Late-Life Depression Frequency and Change During ... Jun 14, 2005 | ||
| Dosage Forms | Capsules | ||
| Drug_Category | Antidepressants; Norepinephrine-Reuptake Inhibitors; ATC:N06AA10 | ||
| Absorption | well absorbed from the GI tract | ||
| Interactions |
Interactions for Nortriptyline: Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when
cimetidine is either added or deleted from the drug regimen. Serious anticholinergic symptoms (severe dry mouth,
urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic
antidepressants when cimetidine is added to the drug regimen. In addition, higher-than expected steady-state serum
concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking
cimetidine. In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum
concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued. The therapeutic
efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued. Several
of the tricyclic antidepressants have been cited in these reports. There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants,
including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.
Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may
affect strategies during conversion from one drug to the other. Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a ìstimulatingî effect in some depressed patients. Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs. The patient should be informed that the response to alcohol may be exaggerated. Drugs Metabolized by P450IID6 óA subset (3% to 10%) of the population has reduced activity of
certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6. Such individuals are referred to as
ìpoor metabolizersî of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants.
These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual
doses. In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic
antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme,
and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs
metabolized by this enzyme system, leading to drug interactions. Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution. | ||
| Toxicity | cardiac dysrhythmias, severe hypotension, shock, congestive heart failure, pulmonary edema, convulsions, and CNS depression, including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic antidepressant toxicity. LD50=mg/kg(orally in rat) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine | ||
| Chemical Formula | C19H21N | ||
| Molecular Weight | 263.377 g/mol | ||
| Smiles String | CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31 | ||
| Melting Point | 213-215°C | ||
| Water Solubility | Not Available | ||
| State | white to off- white powder, having a slight, characteristic odor | ||
| LogP/Hphobicity | 4.298 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 16 and 90 hours | ||
| Protein Binding [%] | highly protein-bound in plasma and tissues | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Nortriptyline.html http://www.rxlist.com/cgi/generic/nortrip.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00602 | ||
| CAS Registry Number | 72-69-5 | ||
| KEGG Compound ID | C07274 | ||
| PubChem ID | SID:149239 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2240789 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |